Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 7,500,000 shares of common stock of Kala Pharmaceuticals, Inc. for approximately $61.9 million before underwriting discounts and estimated expenses of the offering. The common stock is listed on the NASDAQ Global Select Market under the symbol “KALA.”

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary MPP technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Marcel Fausten and associates Jaryn S. Fields and J. Taylor Arabian. The tax team included partner Mario J. Verdolini and associate Dao Fu. Partner Frank J. Azzopardi and associate Tilak Koilvaram provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post